Skip to main content

Day: June 3, 2021

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

MSP-1014 selected based on head-to-head comparison to psilocybin and its active metabolite psilocin MSP-1014 showed greater safety and efficacy in in vitro and in vivo preclinical models Cost effective for cGMP manufacturing and IND-enabling studies TORONTO, June 03, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company“), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has selected its lead clinical candidate, MSP-1014, a differentiated psilocybin-based compound from its Family 1 of novel, patent-pending psychedelic compounds to move forward into current good manufacturing practice...

Continue reading

Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has initiated a new clinical research program for pancreatic cancer (PC) and NP-120 (Ifenprodil). Ifenprodil demonstrated a significant anti-tumour effect in a PC animal model which was reported in a paper published in the Dove Press Journal, Clinical Pharmacology: Advances and Applications. The research paper concluded that Ifenprodil significantly and rapidly reduced the average solid tumour size by approximately 50% by day three and remained stable while on treatment in a murine model of PC. The average tumour size in the untreated group doubled during the same period. PC is an orphan disease and has a five-year survival rate of 7.9%. This means that...

Continue reading

Jowell Global Ltd. Presents Juhao Best Choice Store Business Model At 2021 China (Changshu) International Business Equipment Exposition

Shanghai, China, June 03, 2021 (GLOBE NEWSWIRE) — Jowell Global Ltd. (“JWEL” or the “Company”) (NASDAQ: JWEL), a company which operates one of the leading cosmetics, health and nutritional supplements and household products e-commerce platforms – Juhao Mall in China, today announced that it has presented Juhao Best Choice Store at 2021 China (Changshu) International Business Equipment Exposition to showcase its new innovative online platform plus offline community group-buying retail store business model. Mr. Zhiwei Xu, CEO and Chairman of the Company introduced Juhao Best Choice Store’s marketing and sales model to officials from Changshu local governments, national supply chain association, national commerce and enterprise association and national grocery products for daily use marketing society during the exposition,...

Continue reading

REMINDER: Saputo to Host Webcast to Discuss Fiscal 2021 Fourth Quarter Results and to Present New Global Strategic Plan

MONTREAL, June 03, 2021 (GLOBE NEWSWIRE) — Saputo Inc. (“Saputo”) (TSX:SAP) will release its fiscal 2021 fourth quarter financial results on Thursday, June 3, 2021. A webcast and conference call will be held the same day to discuss the financial results as well as to present Saputo’s new global strategic plan and overarching growth strategy.Start time: 1:30 p.m. (Eastern Time)Duration: approximately 2 hoursWebcast (recommended): https://www.gowebcasting.com/11294Please note, there will be a visual element to the speakers’ presentation.Participants are encouraged to join the webcast for full access to the content.Conference line (audio only): 1-800-785-6502Please dial-in 10 minutes prior to the start time.The webcast will be structured as follows:Remarks on the fiscal 2021 fourth quarter financial results, followed...

Continue reading

VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

Second primary endpoint added following discussion with the U.S. Food and Drug Administration Successfully meeting either PFS or OS primary endpoints expected to be sufficient for submitting a BLA for potential full FDA approval PFS endpoint readout expected in 2022; BLA submission could be possible one year earlier than previously projected with OS endpoint alone Clinical trial amendment reported in an OVAL Clinical Trial in Progress poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingTEL AVIV, Israel, June 03, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced a primary endpoint amendment in the OVAL Phase 3 registration-enabling study of VB-111. The clinical trial amendment included a second, separate primary endpoint, of progression free survival (PFS), in addition...

Continue reading

Abacus Provides Results on Jersey Valley

VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — Abacus Mining & Exploration Corporation (“Abacus” or the “Company”) (TSXV: AME) wishes to announce the results from a recently completed three-hole drilling program on the Jersey Valley epithermal gold property. The Company intercepted similar gold and silver values to historical drilling, with the targets tested further along strike and at slightly greater depth. The best results were a 12.64 metre interval of 0.053 g/t gold and 0.73 g/t silver, including 1.09 g/t silver over 7.55 metres and 0.19 g/t gold and 3.62 g/t silver over 1.5 m. These types of gold systems are found due to the presence of low, subeconomic precious metal values near surface, and it is possible that the Company did not drill deep enough in this first pass of drilling. Sampling of the drill...

Continue reading

Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care

Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) — Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced results from a new utility study. The study confirmed the importance of risk assessment testing in addressing treatment ambiguity in the early stages of diabetic kidney disease (DKD) and improving patient engagement and adherence, two major barriers to slowing or preventing DKD progression and preserving kidney health. In clinical studies, KidneyIntelX has shown to accurately predict progression of DKD, suggesting that KidneyIntelX risk assessment could support primary care physicians in making appropriate treatment decisions and slowing or preventing DKD progression. In this qualitative...

Continue reading

Resgreen Group Announces Relocation of Production and Manufacturing Facility to Shelby Township, Michigan

Shelby Township, Michigan, June 03, 2021 (GLOBE NEWSWIRE) — Resgreen Group International (OTCPINK: RGGI), a leading mobile robot company, announces the relocation of manufacturing and production headquarters to Shelby Township, Michigan. Resgreen Group International has moved to a larger facility to meet the increasing needs and demands of rapid development and fabrication of current and future products. Working in close proximity with a vital supplier, Atlantic Precision Products, RGGI is able to add a new level of quality, efficiency, and momentum to the growth, development and assembly processes. “We are very excited to be expanding into a larger facility and working closely with Atlantic Precision Products in order to increase efficiency in our production and manufacturing process.” said Parsh Patel, CEO of Resgreen Group...

Continue reading

OrthoPediatrics Corp. Completes Senior Leadership Transition with Appointment of David Bailey as Chief Executive Officer

WARSAW, Ind., June 03, 2021 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the senior leadership transition, with David Bailey succeeding Mark Throdahl as Chief Executive Officer. Mark Throdahl will remain with the Company as Executive Chairman. “Over the last 10 years, it has been a privilege to work with our remarkable team leading the effort to improve the lives of children suffering from musculoskeletal disorders,” said Mark Throdahl. “As Executive Chairman, I look forward to remaining highly engaged with OrthoPediatrics and its strategy as well as supporting Dave in his new role as CEO. Dave has been an exemplary executive since joining OrthoPediatrics in 2007, and I have every confidence...

Continue reading

Michael R. Cote to Retire as Secureworks CEO; Board Appoints Wendy K. Thomas as Next President & CEO

ATLANTA, June 03, 2021 (GLOBE NEWSWIRE) — Secureworks® (NASDAQ:SCWX), a global leader in cybersecurity, today announced that Chief Executive Officer Michael R. Cote is retiring as CEO and a member of the Secureworks Board of Directors, effective Sept. 3, 2021. The Secureworks Board of Directors unanimously appointed Wendy K. Thomas, Secureworks’ current President of Customer Success, as the company’s next President and Chief Executive Officer, effective Sept. 3, 2021. “Wendy is a proven and respected leader who has been the driving force of our company’s transformation,” said Mr. Cote. “Her deep knowledge of our business has made her a valued strategic partner for many years, and throughout her tenure she has delivered strong operating results and innovative solutions through a relentless commitment to our customers, our purpose,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.